A Clinical Trial to Assess the Effect of Deforolimus (AP23573; MK-8669) on QTc Interval in Patients (Protocol 037).
Phase of Trial: Phase I
Latest Information Update: 08 May 2014
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Cancer
- Focus Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 14 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Planned end date changed from 1 May 2010 to 1 Apr 2010 as reported by ClinicalTrials.gov.